Supplementary Figures





Figure S2 А В SW480 SW480+ CCD-18Co 2500 Tumor Volume (mm³) 2000 SW480 1500 SW480+ 1000 CCD-18Co 500 10 12 13 0 DLD¹*CD¹8CO^{Vector} 8CO^{SBMA} 0 2 5 2 2 Ś Days Ε С D DLD-1 DLD-1+CCD-18Co Vector DLD-1+CCD-18Co sgRNA 2500-(2000 1500 1000 500 0 *** 0 6 ~ 5 2 0 22 20 Days

Figure S2. (A, B) Tumor growth stimulated by fibroblasts. Nude mice (n = 7 in each group) were injected with adenocarcinoma cancer cells alone (SW480) or together with human normal colonic fibroblasts (SW480+ CCD-18Co). (A) The growth curves of the xenograft tumors. Tumor size was measured at the indicated time points (days). Data are presented as mean \pm s.e.m.. ***, *p* < 0.001 vs control (two-way ANOVA with Bonferroni post-tests). Tumors were excised for histology at the last time point. (B) Photographs of dissected tumor samples. (C) Photographs of nude mice that were injected with human normal colonic fibroblasts (CCD-18Co) alone after 25 days. (D) The growth curves of xenograft tumors in nude mice (n= 7 in each group) that were injected with

adenocarcinoma cancer cells (DLD-1) alone, DLD-1 and transfected fibroblasts with α 5 depletion (SW480+ CCD-18Co sgRNA), or DLD-1 and transfected fibroblasts with vector control (SW480+ CCD-18Co vector). Tumor size was measured at the indicated time points (days). Tumors were excised for histology at the last time point. Data are presented as mean ± s.e.m.. ***, *p* < 0.001 vs control (two-way ANOVA with Bonferroni post-tests). (E) Photographs of dissected tumor samples.



Figure S3

Figure S3. (A) Expression levels of α 5 and selected markers were determined by western blotting in CCD-18Co cells with or without TGF β activation. A representative result of three independent experiments is shown on the left. Quantification of three independent blots for α 5 expression as a ratio relative to the expression level of control cells is shown on the right. Data are presented as mean \pm s.e.m.. ***, *p* < 0.001 vs control (one-way ANOVA). (B) Transcript levels of *ITGA5* and *FN* determined by qPCR. Experiments were performed in triplicate and student's *t*-test was used for statistical analysis.

Figure S4



Figure S4. (A) Expression levels of α 5 and fibronectin were determined by western blotting in CCD-18Co cells treated with no siRNA (Mock) or siRNAs (α 5 oligo1+ α 5oligo2) targeting integrin α 5 (si α 5), non-targeting siRNA was used as a negative control (siCtr). β -actin served as loading control. A representative result of three independent experiments is shown. (B) Immunostaining of fibronectin (red) in CCD-18Co cells treated with or without siRNA. F-actin is stained with phalloidin-647 (red), and DNA was stained with DAPI (blue). Scale bar, 20 µm. (C, D, E, F,) The α 5 knockdown in fibroblasts showed reduced effects on promoting cancer cell migration and invasion compared to the wild-type fibroblasts. DLD-1-GFP cells were co-cultured with wildtype CCD-18Co cells (Mock and siCtr) or with α 5 knockdown CCD-18Co cells (si α 5) in transwell inserts with or without matrigel. After 16 hours, (C, E) Serum-induced transwell migration were calculated. DLD-1-GFP cells migrating to the lower chamber were observed under a fluorescence microscope and were counted. Scale bar, 200 µm. After 22 hours, (D, F) Serum-induced cell invasion were calculated. DLD-1-GFP cells that invaded through the matrigel to the lower chamber were observed under a fluorescence microscope and were counted. Scale bar, 200 µm. Error bars, s.e.m. (n = 3). *, p < 0.05 (one-way ANOVA).





Figure S5. (A) Kaplan-Meier curve of the overall survival of the patients with MAC stratified by *ITGA5* expression in TCGA cohort. Overall survival was analyzed with Kaplan-Meier curve and Log-rank test. (B) Representative double immunofluorescent staining of α 5 (red) and fibronectin (green) with DAPI (blue nuclei) in the clinical samples with colorectal adenocarcinomas. Scale bar, 20 µm. White lines delimitate the area of tumor epithelial cells.

Supplementary Table S1. Characteristics of 355 CRC cases according to α 5 staining status in the independent cohort.

| Characteristics ^a | All cases | α5 staining status | | |
|------------------------------|-------------|--------------------|----------------|--------------------|
| | 355 | High expression | Low expression | р |
| | | 177 (49.9%) | 178 (50.1%) | |
| Age | | | | 0.915 ^b |
| > 63 | 171 (49.7%) | 85(50.0%) | 86 (49.4%) | |
| <=63 | 173 (50.3%) | 85(50.0%) | 88 (50.6%) | |
| Sex | | | | 0.061 ^b |
| Men | 195 (54.9%) | 106 (59.9%) | 89 (50.0%) | |
| Women | 160 (45.1%) | 71 (40.1%) | 89 (50.0%) | |
| Tumor size | | | | 0.283 ^b |
| >4 cm | 160 (45.7%) | 85 (48.6%) | 75 (42.9%) | |
| <=4 cm | 190 (54.3%) | 90 (51.4%) | 100 (57.1%) | |
| Tumor location | | | | 0.732 ^b |
| Proximal colon | 96 (27.0%) | 46 (26.0%) | 50 (28.1%) | |
| Distal colon | 118 (33.2%) | 57 (32.2%) | 61 (34.3%) | |
| Rectum | 141 (39.7%) | 74 (41.8%) | 67 (37.6%) | |
| Local invasion depth | | | | 0.468 ^b |
| Tis/T1/T2 | 82(23.1%) | 38 (21.5%) | 44 (24.7%) | |
| T3/T4 | 273 (76.9%) | 139 (78.5%) | 134 (75.3%) | |
| Lymph node | | | | 0 508 ^b |
| involvement | | | | 0.500 |
| NO | 207 (58.3%) | 98 (55.4%) | 109 (61.2%) | |
| N1 | 99 (27.9%) | 52 (29.4%) | 47 (26.4%) | |
| N2 | 49 (13.8%) | 27 (15.3%) | 22 (12.4%) | |
| Distant metastasis | | | | 0.857 ^c |
| M0 | 322 (90.7%) | 160 (90.4%) | 162 (91.0%) | |
| M1 | 33 (9.3%) | 17 (9.6%) | 16 (9.0%) | |
| Tumor stage | | | | 0.099 ^b |
| 0/I/II | 198 (55.8%) | 91 (51.4%) | 107 (60.1%) | |
| III/IV | 157 (44.2%) | 86 (48.6%) | 71 (39.9%) | |
| Grade | | | | 0.174 ^c |
| Low | 38 (10.7%) | 23 (13.0%) | 15 (8.4%) | |
| Medium or High | 317 (89.3%) | 154 (87.0%) | 163 (91.6%) | |

^aPercentages in all cases or in the corresponding subgroups (High expression or Low expression) were given in the brackets.

 ${}^{b}\chi^{2}$ test.

^cFisher's exact test.